Yahoo Finance

Wellness products company Nature’s Sunshine (NASDAQ:NATR) reported Q1 CY2025 results beating Wall Street’s revenue expectations , with sales up 2% year on year to $113.2 million. The company expects the full year’s revenue to be around $457.5 million, close to analysts’ estimates. Its GAAP profit of $0.25 per share was 51.5% above analysts’ consensus estimates.

Is now the time to buy Nature's Sunshine? Find out in our full research report.

Nature's Sunshine (NATR) Q1 CY2025 Highlights:

• Revenue: $113.2 million vs analyst estimates of $109.3 million (2% year-on-year growth, 3.6% beat)

• EPS (GAAP): $0.25 vs analyst estimates of $0.17 (51.5% beat)

• Adjusted EBITDA: $10.97 million vs analyst estimates of $9.75 million (9.7% margin, 12.5% beat)

• The company reconfirmed its revenue guidance for the full year of $457.5 million at the midpoint

• EBITDA guidance for the full year is $41 million at the midpoint, below analyst estimates of $42.98 million

• Operating Margin: 5.4%, up from 4.2% in the same quarter last year

• Free Cash Flow was $1.50 million, up from -$1.50 million in the same quarter last year

• Market Capitalization: $231 million

“2025 got off to a strong start, as first quarter revenue came in at $113 million, up 5% on a constant currency basis, and adjusted EBITDA came in at $11 million, up 20% versus prior year,” said Terrence Moorehead, CEO of Nature’s Sunshine.

Company Overview

Started on a kitchen table in Utah, Nature’s Sunshine (NASDAQ:NATR) manufactures and sells nutritional and personal care products.

Sales Growth

Reviewing a company’s long-term sales performance reveals insights into its quality. Any business can have short-term success, but a top-tier one grows for years.

With $456.6 million in revenue over the past 12 months, Nature's Sunshine is a small consumer staples company, which sometimes brings disadvantages compared to larger competitors benefiting from economies of scale and negotiating leverage with retailers.

As you can see below, Nature's Sunshine struggled to increase demand as its $456.6 million of sales for the trailing 12 months was close to its revenue three years ago. This shows demand was soft, a poor baseline for our analysis.

This quarter, Nature's Sunshine reported modest year-on-year revenue growth of 2% but beat Wall Street’s estimates by 3.6%.

Looking ahead, sell-side analysts expect revenue to grow 1.6% over the next 12 months, similar to its three-year rate. While this projection implies its newer products will fuel better top-line performance, it is still below the sector average.